GlassScriptPhysician profile
Daniel Esteban Bujanda
NPI 1285993501
$8,105.02
in general payments reported to CMS, 2019-2025
23 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,031 · 2020: $171 · 2021: $123 · 2022: $74.67 · 2023: $482 · 2024: $2,074 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,104 · Travel and Lodging: $534 · Education: $68.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,103.99 |
| Travel and Lodging | $533.72 |
| Education | $68.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,275.47 | 2019-2021 | |
| Janssen Biotech, INC. | $999.83 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Cook Medical LLC | $800.00 | 2019 | |
| Medtronic, INC. | $757.70 | 2024-2025 | Interstim |
| Abbvie INC. | $555.59 | 2022-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $347.45 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $269.47 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.12 | 2019-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $177.55 | 2024 | Voquezna |
| Ardelyx, INC. | $154.05 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $82.87 | 2024-2025 | Zenpep |
| Celgene Corporation | $78.19 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $72.34 | 2019 | |
| Madrigal Pharmaceuticals | $49.81 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $48.33 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $47.08 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $26.98 | 2025 | Iqirvo |
| Organon LLC | $25.19 | 2024 | |
| Conmed Corporation | $21.33 | 2019 | |
| Celltrion USA INC. | $20.23 | 2024 | Zymfentra |
| Intercept Pharmaceuticals, INC. | $19.48 | 2023 | Ocaliva |
| Lilly USA, LLC | $18.13 | 2024 | Omvoh |
| Echosens North America, INC. | $16.83 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bujanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.